Skip to contentS
Sigyn Therapeutics, Inc.
S
SIGYSigyn Therapeutics, Inc. Q4 2018 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$1.22M-$1.22MderivedN/M vs Q4 2017 EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived-$355,784N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
Operating Incomederived$68,179N/M Operating Cash Flowderived$12,321N/M Free Cash Flowderived$10,231N/M ended Dec 31, 2018 · filed Apr 1, 2019 · 91 d after period end